Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
| Roche, Merck, AstraZeneca and Abbott to Invest Heavily in Colorectal Cancer Studies | ||
| By: PR Newswire Association LLC. - 30 Sep 2016 | Back to overview list |
|
HYDERABAD, India, September 30, 2016 /PRNewswire/ -- Mordor Intelligence announces the publication of their research report on the colorectal cancer market. The report titled, "Global Colorectal Cancer Diagnostics and Therapeutics Market - Growth, Trends & Forecast," discusses the current landscape and outlook of the market. The global colorectal cancer market is estimated to account USD 8 billion in 2016 and is forecasted to reach USD 10.7 billion by 2021, while projecting a CAGR of approx. 6% during the forecast period (2016-2021). The report is an amalgamation of the current market scenario, its prospects and factors driving and restraining the market growth. It provides deep insights on the North America, Europe, and Asia Pacific colorectal cancer markets. Our report on colorectal cancer diagnostics and therapeutics market is segmented as follows:
The global cancer diagnostics and therapeutics market has been segmented by diagnostics (fecal blood tests, flexible sigmoidoscopy, colonoscopy, virtual colonoscopy, double contrast barium enema and others), by therapeutics (chemotherapy, immunotherapy, chemoprotectants). Chemotherapy has been further segmented into antimetabolites (Fluorouracil and Capecitabine) and alkylating agents; and immunotherapy has been further segmented into Bevacizumab, Cetuximab, and Panitumumab. The market has been geographically segmented into North America, Europe, Asia-Pacific, and Rest of the World. The colorectal cancer therapeutics is the largest segment, which is expected to record an estimated market value of USD 6.4 billion in 2016. The North American and European regions currently dominate the market owing to their increasing healthcare expenditure, high incidences of cancer, improved reimbursement policies and the launch of high priced cancer maintenance therapies. Some of the industry players profiled in the report include: Roche, Merck, AstraZeneca, Abbott, Epigenomics AG, Exact Sciences Corporation, FujireBio Inc., Genomictree Inc., Metabiomics Corporation, Oncocyte Corporation, Quest Diagnostics, Randox Laboratories, VolitionRx among others. About Mordor Intelligence: Mordor Intelligence is a global market research and consulting firm. Our focus is to provide research insights to facilitate business success. Our research expertise covers niche segments under Agriculture, Healthcare, ICT, Chemicals, Manufacturing, Logistics, Electronics and Automotive, among others. We believe in data, and we provide solutions through it. Optimum solutions and goal-oriented strategies define our endeavors and make us the preferred choice for clients. For information regarding permissions and sales, please contact: info@mordorintelligence.com
|
||
|
||
 | Back to overview list | |